Sept 10 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it would require new language on the labels of long-acting and extended-release opioids, restricting their use and underscoring dangers of abuse, death and damage to newborns of mothers taking the widely used pain medicines.

The FDA also said it would require additional studies of such medicines to assess known risks of abuse, overdose and death.